Development of mGluR5 Antagonists to Treat Fragile X Syndrome and Autism

$2,587,460U01FY2008MHNIH

Seaside Therapeutics, Llc, Cambridge MA

Investigators

Randall L Carpentercontact

View original record on NIH RePORTER →